Just some thoughts20 Jul 2020 12:03
Given what one RNS has done for SNG and where their product is in the cycle of the virus, Avacta seems well placed to stand out from the crowd with something that doesn't appear to be going away any time soon. (Well done to those in SNG)
We await an improved sensitivity and specificity on a ten minute saliva test that works.
We have a BAMS assay test to assist hospital testing.
We have a potential "stop you getting it" affimer (that likely requires a major pharma partner)
We are involved with water testing capabilities that will provide a lifeline to the cruise industry and an early warning system for towns and cities
We have cancer and other pipeline offerings that are not covid related
All may have different timelines but each provides a key inflection point for the company.
Worth thinking about as we sit just above the placing price that has provided a sound financial footing for the company.
Not wearing any rose tinted glasses, just looking at what is there.
All the best.